(Q84894409)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22931715%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Natalizumab risk stratification: role of a two- step anti-JCV antibody assay (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22931715%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Paul W O'Connor

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22931715%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

1 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22931715%20AND%20SRC:MED&resulttype=core&format=json

Canadian Journal of Neurological Sciences

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22931715%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22931715%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22931715%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

670-675

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22931715%20AND%20SRC:MED&resulttype=core&format=json

Use of natalizumab in multiple sclerosis patients

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

Anti-JC virus antibodies: implications for PML risk stratification

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML)

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

Progressive multifocal leukoencephalopathy and natalizumab

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

1 reference

https://api.crossref.org/works/10.1017%2FS031716710001547X

7 January 2021

10.1017/S031716710001547X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22931715%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference